Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials

被引:0
作者
Fausto Petrelli
Karen Borgonovo
Mary Cabiddu
Veronica Lonati
Sandro Barni
机构
[1] Oncology Unit,
[2] Azienda Ospedaliera Treviglio-Caravaggio,undefined
来源
Journal of Cancer Research and Clinical Oncology | 2012年 / 138卷
关键词
Erythropoiesis-stimulating agents; Parenteral iron; Oral iron; Anemia; Hematopoietic response; Solid tumors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:179 / 187
页数:8
相关论文
共 54 条
[1]  
Auerbach M(2004)Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J Clin Oncol 22 1301-1307
[2]  
Ballard H(2010)Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia Am J Hematol 85 655-663
[3]  
Trout JR(2008)Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia J Clin Oncol 26 1611-1618
[4]  
Auerbach M(1998)Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group J Clin Oncol 16 3412-3425
[5]  
Silberstein PT(2001)Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2875-2882
[6]  
Webb RT(2003)Hepcidin a key regulator of iron metabolism and mediator of anemia of inflammation Blood 102 783-788
[7]  
Bastit L(1997)Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 15 1218-1234
[8]  
Vandebroek A(2003)Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study Br J Haematol 122 394-403
[9]  
Altintas S(2007)Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 21 627-632
[10]  
Demetri GD(2004)Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alpha (EPO) therapy Proc Am Soc Clin Oncol 23 747-242